

REMARKS

Entry of the foregoing amendment to the Specification is requested to comply with the requirements of 37 C.F.R. 1.78(a)(2). The claims of the subject application have been amended to avoid multiple dependency. Favorable consideration of the application is respectfully requested.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: Mary Ann Dillahunty
Mary Ann Dillahunty
Registration No. 34,576

P.O. Box 1404
Alexandria, Virginia 22313-1404
(650)622-2300

Date: April 10, 2001

20100507 22220860

Attachment to Preliminary Amendment dated April 10, 2001

Marked-up Claims 3, 6, 7, 16, 17, 24, 32 and 44

3. (Amended) The method according to claim [3] 1 wherein said HIV functional activity is HIV replication.
6. (Amended) The method according to [any one of claims 1 to 5] claim 1 wherein said agent is an amiloride analogue or functional equivalent thereof.
7. (Amended) The method according to claim 6 wherein said amiloride analogue comprises a substitution of the amino group at the 5- position of the pyrazine ring [of] or functional equivalent thereof.
16. (Amended) The method according to [any one of claims 12 to 15] claim 12 wherein said agent is an amiloride analogue or functional equivalent thereof.
17. (Amended) The method according to claim 16 wherein said amiloride analogue comprises a substitution of the amino group at the 5-position of the pyrazine ring [of] or functional equivalent thereof.
24. (Amended) Use according to claim 22 [or 23] wherein said agent is an amiloride analogue or functional equivalent thereof.
32. (Amended) The method according to [any one of claims 30 or 31] claim 30 wherein said amiloride analogue comprises a substitution of the amino group of the 5- position of the pyrazine ring or functional equivalent thereof.

44. (Amended) A pharmaceutical composition for use in reducing, retarding or otherwise inhibiting Vpu ion channel functional activity said composition comprising an agent as defined in accordance with [any one of claims 1 to 21] claim 1 and one or more pharmaceutical acceptable carriers and/or diluents.

2010-02-22 10:00